

Oral Program

Sunday, June 11 2017

1100-14:00	Registration
	Opening & Session 1: Inflammation and Tumorigenesis
14:00-14:15	Welcome and introduction
14:15-15:00	[K01] Metabolic interventions for improving anticancer immunosurveillance Guido Kroemer, <i>French Medical Research Council (INSERM), France</i>
15:00-15:30	[INV01] Chronic inflammation suppresses cancer immunosurveillance: New insights to tumor Immunology from an immunogenic mouse model of liver cancer Michael Karin, <i>University of California San Diego, USA</i>
15:30-16:00	Refreshments Break
16:00-16:30	[INV02] HMGB1 and other DAMPs in the regulation of inflammation and cancer Tadatsugu Taniguchi, <i>The University of Tokyo, Japan</i>
16:30-17:00	[INV03] Intracellular innate immune receptors: regulators of inflammation and cancer Jenny P.Y. Ting, <i>University of North Carolina, USA</i>
17:00-17:15	[ST01] Tuft cells in pancreatic intraepithelial neoplasia alter macrophage populations to mediate pancreatic tumorigenesis G-Y. Liou ¹ , L. Bastea ¹ , A. Fleming ¹ , H. Doeppler ¹ , B. Edenfield ¹ , D.W. Dawson ² , L. Zhang ¹ , N. Bardeesy ³ , P. Storz ^{*1} , ¹ Mayo Clinic, USA, ² UCLA, USA, ³ Harvard Medical School, USA

Monday, June 12 2017

08:00-09:00	Workshop
	Session 2: The Immune System and the Tumor Microenvironment
09:00-09:30	[INV04] Heterotypic epithelial/fibroblast cell-cell contacts as mechanism of sensing tissue disruption in cancer Erik Sahai, <i>The Francis Crick Institute, UK</i>
09:30-10:00	[INV05] Is the right flavor of inflammation the key to successful cancer therapy? Romina Goldszmid, <i>National Institute of Health, USA</i>
10:00-10:30	[INV06] Molecular basis of T cell exhaustion: Insights for immunotherapy John Wherry, <i>University of Pennsylvania, USA</i>
10:30-11:00	Refreshments Break
	Session 2: The Immune System and the Tumor Microenvironment continues...
11:00-11:30	[INV07] Immuno-metabolic programs controlled by ER stress in cancer Juan R. Cubillos-Ruiz, <i>Weill Cornell Medical College, USA</i>
11:30-12:00	[INV08] Mitochondrial priming by CD28 Erika Pearce*, R. K. Goltink, <i>Max Planck Institute of Immunobiology and Epigenetics, Germany</i>
12:00-12:15	[ST02] Regulatory T-cells promote an immunosuppressive tumor microenvironment by protection M2-like tumor-associated macrophages from terminal ER stress through modulation of their lipid metabolism C. Liu ^{*1} , M. Chikina ¹ , S.G. Wendell ² , C.J. Workman ¹ , D.A.A. Vignali ^{1,3} ¹ University of Pittsburgh School of Medicine, USA, ² Clinical Translational Science Institute, University of Pittsburgh School of Medicine, USA, ³ Tumor Microenvironment Center, University of Pittsburgh Cancer Institute, USA
12:15-12:30	[ST03] IL33 orchestrates the brain tumor microenvironment to promote glioma progression A. De Boeck ^{*1} , X. Lun ¹ , B-Y. Ahn ¹ , Y. Shen ² , M. Alshehri ¹ , N-H. Dang ¹ , X. Wang ¹ , X. Hao ¹ , K-A. Goring ¹ , J. King ¹ et al ¹ University of Calgary, Canada, ² University of British Columbia, Vancouver, Canada
12:30-13:30	Meet the Editors with Lunch
13:30-14:45	Poster Session 1
	Session 3: Cancer Therapeutics I
15:00-15:30	[INV09] PD-1 cancer immunotherapy Gordon Freeman, <i>Dana-Farber Cancer Institute, USA</i>
15:30-16:00	[INV10] Tissue-specificity of myeloid-mediated T-cell suppression in solid tumors Lisa Coussens, <i>Oregon Health & Science University, USA</i>
16:00-16:15	[ST04] Exhaustion-associated regulatory regions in CD8⁺ tumor-infiltrating T cells G.P. Mognol ^{*1} , R. Spreafico ² , V. Wong ¹ , J.P. Scott-Browne ¹ , S. Togher ¹ , A. Hoffmann ² , P.G. Hogan ¹ , A. Rao ^{1,3} , S. Trifari ¹ , ¹ La Jolla Institute for Allergy and Immunology, USA, ² University of California, USA, ³ Sanford Consortium for Regenerative Medicine, USA

16:15-16:45	Refreshment Break
	Session 3: Cancer Therapeutics I continues...
16:45-17:15	[INV11] Targeting IL-1 in breast cancer Karolina Palucka, <i>The Jackson Laboratory Cancer Center, USA</i>
17:15-17:45	[INV12] Melanoma neoantigen identification and clinical validation Gerry Linette, <i>University of Pennsylvania, USA</i>
17:45-18:00	[ST05] Distinct roles for hematopoietic and nonhematopoietic PD-L1 in tumor-specific CD8⁺ T cell suppression R.S. Lane*, A. Breazeale, A.W. Lund, <i>Oregon Health & Science University, USA</i>
18:00-18:15	[ST06] Class IIa HDAC inhibition promotes an anti-tumor macrophage phenotype that induces breast tumor regression and inhibits metastasis J.L. Guerriero* ¹ , A. Sotayo ¹ , H.E. Ponichtera ¹ , J.A. Castrillon ¹ , A.L. Pourzia ¹ , S. Schad ¹ , S.F. Johnson ¹ , M. Lobera ¹ , M.A. Nolan ¹ , A. Letai ¹ et al, ¹ Dana-Farber Cancer Institute, USA, ² Brigham and Women's Hospital, USA, ³ Harvard Medical School, USA, ⁴ GlaxoSmithKline, USA
19:00-22:30	Meet the Speakers Dinner – ticket holders only
Tuesday, June 13 2017	
	Session 4: Tumor Immunosurveillance & Defense
09:00-09:30	[INV13] On the role of adaptive and innate immune cells in fatty liver disease and subsequent liver cancer Mathias Heikenwälder, <i>German Cancer Research Center, Germany</i>
09:30-10:00	[INV14] Regulation of dendritic cell accumulation in tumours as an immune checkpoint Caetano Reis e Sousa, <i>The Francis Crick Institute, UK</i>
10:00-10:15	[ST07] Characterizing the role of CD11b⁺ dendritic cell subsets in priming anti-tumor CD4 T cell responses A. Mujal*, E. Roberts, M. Binnewies, A. Gerard, M. Krummel, <i>UCSF, USA</i>
10:15-10:30	[ST08] Tumor secreted Pros1 inhibits macrophage M1 polarization E. Ubil*, L. Caskey, C. Story, D. Hunter, H.S. Earp III, <i>University of North Carolina at Chapel Hill, USA</i>
10:30-11:00	Refreshment Break
	Session 4: Tumor Immunosurveillance & Defense continues...
11:00-11:30	[INV15] Cancer assassins: The secrets of serial killer cells Gillian Griffiths, <i>Cambridge Institute for Medical Research, UK</i>
11:30-12:00	[INV16] Visualizing tumor immune interactions real time Matthew F. Krummel, <i>University of California San Francisco, USA</i>
12:00-12:15	[ST09] Amphiregulin produced by CD4⁺ T cells promotes lung tumor growth independently of the anti-tumor immune response J.A. Green*, N. Arpaia, M. Schizas, A.Y. Rudensky, <i>Memorial Sloan-Kettering Cancer Center, USA</i>
12:15-12:30	[ST10] Granulocytes are active players in the CLL microenvironment S. Ozturk*, A. Madi, P. Lichter, M. Seiffert, <i>DKFZ, Germany</i>
12:30-13:30	Lunch
13:30-14:45	Poster Session 2
	Session 5: Cancer Therapeutics II
15:00-15:30	[INV17] Control of immune and vascular signaling programs in cancer by targeting lectin-glycan interactions Gabriel Rabinovich, <i>The National Scientific and Technical Research Council, Argentina</i>
15:30-16:00	[INV18] Vaccine based combinatorial immunotherapy converts pancreatic cancer into an immunologic disease Liz Jaffee, <i>Johns Hopkins School of Medicine, USA</i>
16:00-16:30	[INV19] TBD Michel Sadelain, <i>Memorial Sloan Kettering Cancer Center, USA</i>
16:30-17:00	Refreshment Break
	Session 5: Cancer Therapeutics II continues...
	[K02] Chimeric Antigen Receptor Therapy for Cancer: Progress and Challenges Crystal Mackall, <i>Stanford University, USA</i>
17:45-18:00	Closing Remarks